MG
RXRX icon

Marex Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Marex Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-344,500
Closed -$1.74M – 985
2025
Q2 		$1.74M Buy
+344,500
New +$1.69M 0.02% 239

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Marex Group's RXRX Position: Q1 2026 in Review

Marex Group opened a new position in Recursion Pharmaceuticals (RXRX) in Q1 2026: 32,788 shares worth $101K. The stake represents ﹤0.01% of the portfolio and ranks #944 among its holdings. This is a return to the name: Marex Group previously reported a position in RXRX as recently as Q2 2025.

Marex Group first reported a position in RXRX in Q2 2025 and has held it in 2 quarters since. The position peaked at $1.8M in Q2 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Marex Group held 32,788 shares of Recursion Pharmaceuticals worth $101K as of Q1 2026.
  • Recursion Pharmaceuticals was a new Marex Group position in Q1 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Marex Group's portfolio in Q1 2026, its #944 holding.
  • Marex Group first reported a position in Recursion Pharmaceuticals in Q2 2025 and has held it in 2 quarters since.
  • Marex Group's Recursion Pharmaceuticals position peaked at $1.8M in Q2 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Marex Group's 13F filing for Q1 2026, filed 13 May 2026.